Cargando…

Functionally impaired antibody response to BNT162b2 booster vaccination in CVID IgG responders

BACKGROUND: Although previous studies described the production of IgG antibodies in a subgroup of patients with common variable immunodeficiency (CVID) following messenger RNA vaccinations with BNT162b2 severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (CVID responders), the functionality...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sauerwein, Kai M.T., Geier, Christoph B., Stemberger, Roman F., Rossmanith, Raphael, Akyaman, Hüseyin, Illes, Peter, Fischer, Michael B., Eibl, Martha M., Walter, Jolan E., Wolf, Hermann M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Academy of Allergy, Asthma & Immunology 2023
Materias:	Covid-19
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9715258/ https://www.ncbi.nlm.nih.gov/pubmed/36463978 http://dx.doi.org/10.1016/j.jaci.2022.11.013

Ejemplares similares

Antigen-Specific CD4(+) T-Cell Activation in Primary Antibody Deficiency After BNT162b2 mRNA COVID-19 Vaccination
por: Sauerwein, Kai M. T., et al.
Publicado: (2022)

First manifestation of AQP4-IgG-positive neuromyelitis optica spectrum disorder following the COVID-19 mRNA vaccine BNT162b2
por: Umezawa, Shu, et al.
Publicado: (2022)

Guillain-Barré syndrome following BNT162b2 COVID-19 vaccine
por: Trimboli, Michele, et al.
Publicado: (2021)

Aseptic meningitis after vaccination of the BNT162b2 mRNA COVID-19 vaccine
por: Saito, Kazuyuki, et al.
Publicado: (2021)

Spinal cord ischemia complicating BNT162b2 mRNA COVID-19 vaccination
por: Fotiadou, Aggeliki, et al.
Publicado: (2022)

Guillain–Barré syndrome associated with BNT162b2 COVID vaccination: a first case report from South Korea
por: Kim, Namkyun, et al.
Publicado: (2022)

Functional CVIDs phenotype clusters identified by the integration of immune parameters after BNT162b2 boosters
por: Piano Mortari, Eva, et al.
Publicado: (2023)

Six-month humoral response to BNT162b2 mRNA COVID-19 vaccine in people with multiple sclerosis treated with natalizumab
por: Altieri, Manuela, et al.
Publicado: (2022)

COV-BT Ire study: safety and efficacy of the BNT162b2 mRNA COVID-19 vaccine in patients with brain tumors
por: Tanzilli, Antonio, et al.
Publicado: (2022)

Status migrainosus: a potential adverse reaction to Comirnaty (BNT162b2, BioNtech/Pfizer) COVID-19 vaccine—a case report
por: Consoli, Stefano, et al.
Publicado: (2021)

Myelin oligodendrocyte glycoprotein antibody-associated optic neuritis following third dose of BNT162b2 COVID-19 vaccine in a patient with systemic lupus erythematosus
por: Kang, Minsung, et al.
Publicado: (2023)

Waning of first- and second-dose ChAdOx1 and BNT162b2 COVID-19 vaccinations: a pooled target trial study of 12.9 million individuals in England, Northern Ireland, Scotland and Wales
por: Kerr, Steven, et al.
Publicado: (2022)

Single dose of BNT162b2 mRNA vaccine against severe acute respiratory syndrome coronavirus‐2 (SARS‐CoV‐2) induces neutralising antibody and polyfunctional T‐cell responses in patients with chronic myeloid leukaemia
por: Harrington, Patrick, et al.
Publicado: (2021)

Reactogenicity after the first and second doses of BNT162b2 mRNA coronavirus disease vaccine: a single-center study
por: Kang, Yu Min, et al.
Publicado: (2021)

Characterizing healthcare worker attitudes toward the bivalent COVID-19 booster
por: Willebrand, Kathryn, et al.
Publicado: (2023)

Vaccine and Psychological Booster: Factors Associated With Older Adults’ Compliance to the Booster COVID-19 Vaccine in Israel
por: Ben-David, Boaz M., et al.
Publicado: (2022)

Primary COVID-19 vaccine cycle and booster doses efficacy: analysis of Italian nationwide vaccination campaign
por: Mattiuzzi, Camilla, et al.
Publicado: (2022)

Predictors of COVID-19 booster vaccine hesitancy among fully vaccinated adults in Korea: a nationwide cross-sectional survey
por: Noh, Yunha, et al.
Publicado: (2022)

SG-APSIC1158: COVID-19 vaccine booster hesitancy among healthcare workers: A retrospective observational study in Singapore
por: Koh, Sky Wei Chee, et al.
Publicado: (2023)

Does ChAdOx1-S and BNT162b2 heterologous prime-boost vaccination trigger higher rates of vaccine-related adverse events?
por: Haji, Alhan, et al.
Publicado: (2023)

Comparative analyses of IgG/IgA neutralizing effects induced by three COVID-19 vaccines against variants of concern
por: Lafon, Eliott, et al.
Publicado: (2022)

Safety and efficacy of the BNT162b2 mRNA COVID-19 vaccine during Ixekizumab treatment for hidradenitis suppurativa
por: Iannone, Michela, et al.
Publicado: (2021)

Comparative effectiveness of different primary vaccination courses on mRNA-based booster vaccines against SARs-COV-2 infections: a time-varying cohort analysis using trial emulation in the Virus Watch community cohort
por: Nguyen, Vincent Grigori, et al.
Publicado: (2023)

Investigation of Anti-SARS-CoV-2 IgG and IgM Antibodies in the Patients with COVID-19 by Three Different ELISA Test Kits
por: Nagasawa, Masayuki, et al.
Publicado: (2020)

Anti-SARS-Cov-2 IgA in Current Scenario of IgM and IgG Rapid Test: a New Alternative for the Diagnostic of COVID-19
por: La Rosa Fabián, Christian, et al.
Publicado: (2020)

Frosted branch angiitis after booster vaccination with BNT162b2
por: Haas, A.-M., et al.
Publicado: (2023)

Using Anti-SARS-CoV-2 IgG and IgM Antibodies to Detect Outpatient Cases with Olfactory and Taste Disorders Suspected as Mild Form of COVID-19: a Retrospective Survey
por: Taziki Balajelini, Mohammad Hosein, et al.
Publicado: (2020)

Nasal vaccine as a booster shot: a viable solution to restrict pandemic?
por: Meenakshi, Sarasa, et al.
Publicado: (2022)

Are COVID-19 vaccines safe for people with epilepsy? A cross-sectional study
por: Özdemir, Hüseyin Nezih, et al.
Publicado: (2022)

Risk factors for the delayed viral clearance in COVID‐19 patients
por: Chen, Xiaoping, et al.
Publicado: (2021)

Crisis Symptom Management and Patient Communication Protocols Are Important Tools for All Clinicians Responding to COVID-19
por: Bowman, Brynn A., et al.
Publicado: (2020)

Ready to respond: adapting rapid response team training in Papua New Guinea during the COVID-19 pandemic
por: Marsh, Celeste, et al.
Publicado: (2022)

A definite case of Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) induced by administration of the Pfizer/BioNTech BNT162b2 vaccine for SARS-CoV2
por: Schroeder, Jan Walter, et al.
Publicado: (2022)

Spontaneous NLRP3 inflammasome-driven IL-1-β secretion is induced in severe COVID-19 patients and responds to anakinra treatment
por: Bertoni, Arinna, et al.
Publicado: (2022)

BNT162b2 Vaccine Booster and Mortality Due to Covid-19
por: Arbel, Ronen, et al.
Publicado: (2021)

Protection of BNT162b2 Vaccine Booster against Covid-19 in Israel
por: Bar-On, Yinon M., et al.
Publicado: (2021)

Reopening Oral Health Services during the COVID-19 Pandemic through a Knowledge Exchange Coalition
por: McNally, M., et al.
Publicado: (2021)

Anti-SARS-CoV-2 IgG antibodies in patients with or without SARS-CoV-2 infection after BNT162b2 vaccine booster
por: Salvagno, G.L., et al.
Publicado: (2022)

IgG serum levels in CVID patients during pregnancy
por: Pavan-Ramos, Tatiane, et al.
Publicado: (2015)

Characteristics of US Adults Delaying Dental Care Due to the COVID-19 Pandemic
por: Kranz, A.M., et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_f4bge8376e170uhknm56arust9